China Journal of Oral and Maxillofacial Surgery ›› 2022, Vol. 20 ›› Issue (4): 366-370.doi: 10.19438/j.cjoms.2022.04.009

• Original Articles • Previous Articles     Next Articles

Effect of Nrf2 on TPF induced chemotherapy for oral squamous cell carcinoma

ZHAO Xiao-mei, XIA Rong-hui, ZHONG Lai-ping, ZHU Dong-wang, ZHANG Zhi-yuan   

  1. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China
  • Received:2022-03-14 Revised:2022-05-20 Online:2022-07-20 Published:2022-08-02

Abstract: PURPOSE: To examine the expression of nuclear factor erythroid-2 related factor (Nrf2) in oral squamous cell carcinoma (OSCC) and investigate the effect of Nrf2 on TPF induced chemotherapy. METHODS: A total of 65 patients with OSCC who received TPF chemotherapy were selected. Nrf2 expression in the biopsy specimens before treatment was examined by immunohistochemistry. The correlations between Nrf2 expression and clinical factors and clinical response to TPF induced chemotherapy were analyzed. SPSS 23.0 software package was used for data analysis. RESULTS: Survival analysis showed that Nrf2 expression was significantly correlated with the prognosis of TPF induced chemotherapy in OSCC patients. Patients with higher Nrf2 expression had better overall survival, disease-free survival, local relapse-free survival and distant metastasis free survival. Univariate and multivariate Cox analysis showed that Nrf2 was an independent prognostic risk factor for TPF chemotherapy in OSCC patients. CONCLUSIONS: The expression of Nrf2 is correlated with the efficacy of TPF induced chemotherapy in OSCC patients. Patients with low Nrf2 have a better prognosis, and Nrf2 can be used as a biomarker to predict the efficacy of TPF induced chemotherapy in OSCC patients

Key words: Nrf2, Oral squamous carcinoma, TPF induced chemotherapy, Prognosis

CLC Number: